The GABAA receptor: a novel target for treatment of fragile X?

@article{DHulst2007TheGR,
  title={The GABAA receptor: a novel target for treatment of fragile X?},
  author={Charlotte D’Hulst and R. Frank Kooy},
  journal={Trends in Neurosciences},
  year={2007},
  volume={30},
  pages={425-431}
}
GABA(A) receptors are the major inhibitory neurotransmitter receptors in the mammalian brain, implicated in anxiety, depression, epilepsy, insomnia, and learning and memory. Here, we present several lines of evidence for involvement of the GABAergic system, and in particular the GABA(A) receptor-mediated function, in fragile X syndrome, the most common form of inherited mental retardation. We argue that an altered expression of the GABA(A) receptor has neurophysiologic and functional… Expand
The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome
TLDR
It is shown that the previously reported underexpression of specific subunits of the GABAA receptor can be corrected in YAC transgenic rescue mice, containing the full-length human FMR1 gene in an Fmr1 knockout background and that FMRP directly binds several GAB AA receptor mRNAs. Expand
Involvement and Therapeutic Potential of the GABAergic System in the Fragile X Syndrome
TLDR
The GABAergic system clearly emerges as an attractive target for therapy of the fragile X syndrome, and thus provides an excellent example of how genetic research can lead to unique opportunities for treatment. Expand
Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model
TLDR
It is proved that the GABA(A) receptor is still sensitive to GABAergic drugs as the sedative effect of diazepam resulted in a decreased latency time on the rotarod and alphaxalone had a clear anxiolytic effect in the elevated plus maze. Expand
The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders
TLDR
It is argued that the GABAergic system is disturbed in many neurodevelopmental disorders, including fragile X syndrome, Rett Syndrome, and Dravet syndrome, and is a key candidate target for therapeutic intervention. Expand
Tonic GABAA-Receptor-Mediated Inhibition in Fragile-X Syndrome: A Cause of Dysfunction or a Pathway for a Cure?
TLDR
This chapter will highlight specific examples of defective and reduced GABAA-receptor-mediated tonic inhibitory neurotransmission as a contributing factor to the hyperexcitable phenotype observed in FXS. Expand
The complexity of the GABAA receptor shapes unique pharmacological profiles.
TLDR
The unique physiological and pharmacological properties of the multitude of GABA(A) receptor subtypes present in the central nervous system, making this receptor an important target for novel rational drug therapy are discussed. Expand
Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model
TLDR
Evidence from studies in mice demonstrates that GABA, the major inhibitory neurotransmitter in the brain, and its receptors, is involved in the pathogenesis of FXS, and several FXS phenotypes could be corrected in Fmr1 KO mice after acute treatment with GABAB agonists. Expand
Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome
TLDR
It is shown that the potentiation of extrasynaptic GABA receptors alone, by gaboxadol, is sufficient to normalize numerous behavioral deficits in the FXS model using endpoints that are directly translatable to the clinical presentation of FXS. Expand
Pharmacological treatments for fragile X syndrome based on synaptic dysfunction.
  • M. Telias
  • Medicine
  • Current pharmaceutical design
  • 2019
TLDR
This article summarizes and analyzes the main hypotheses proposed to explain synaptic dysregulation in FXS, by reviewing the scientific evidence that led to pharmaceutical clinical trials and their outcome. Expand
Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS)
TLDR
Upregulation of many components of the GABAergic system in cerebellum, but not in cortex is found, consistent with the cerebellar phenotype of FXTAS patients and has implications for the mechanism causative of differential gene expression. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
Decreased GABAA receptor expression in the seizure-prone fragile X mouse
TLDR
The absence of Fmrp leads to GABAergic system alterations that could account for the increased seizure susceptibility of the fragile X mouse, and these alterations may be relevant to the seizures and the abnormal behaviors in the human syndrome. Expand
Decreased expression of the GABAA receptor in fragile X syndrome
After our initial discovery of under expression of the GABA(A) receptor delta subunit in a genome wide screening for differentially expressed mRNAs in brain of fragile X mice, a validated model forExpand
Further potential of the GABA receptor in the treatment of insomnia
Abstract The benzodiazepine binding site on the GABA A receptor is the target for the majority of hypnotics, including the nonbenzodiazepine ‘Z drugs' (zaleplon, zolpidem, zopiclone and eszopiclone).Expand
The mGluR theory of fragile X mental retardation
TLDR
Loss of fragile X mental retardation protein (FMRP), the defect responsible for fragile X syndrome in humans, increases LTD in mouse hippocampus, consistent with the growing evidence that FMRP normally functions as a repressor of translation of specific mRNAs. Expand
The neuroanatomy and neuroendocrinology of fragile X syndrome.
TLDR
A review of structural imaging studies of individuals with the full mutation shows that several brain regions are enlarged, including the hippocampus, amygdala, caudate nucleus, and thalamus, even after controlling for overall brain volume, and a number of neuroendocrine studies implicating hypothalamic dysfunction in FXS are reviewed. Expand
Neurosteroids, GABAA receptors, and ethanol dependence
TLDR
Chronic ethanol exposure elicits changes in the subunit composition of GABAARs, which, in turn, likely contribute to changes in receptor function associated with the altered pharmacological and behavioral sensitivity characteristic of ethanol tolerance and dependence. Expand
GABAergic Mechanisms in Epilepsy
Summary: γ‐Aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the cerebral cortex, maintains the inhibitory tone that counterbalances neuronal excitation. When this balance isExpand
First genetic evidence of GABAA receptor dysfunction in epilepsy: a mutation in the γ2-subunit gene
TLDR
Analysis of the mutated and wild-type alleles in Xenopus laevis oocytes confirmed the predicted effect of the mutation, a decrease in the amplitude of GABA-activated currents, providing the first genetic evidence that a GABAA receptor is directly involved in human idiopathic epilepsy. Expand
A new benzodiazepine pharmacology.
TLDR
Rational drug targeting to specific receptor subtypes has now become possible, and only restricted neuronal networks will be modulated by the new subtype-selective drugs. Expand
Mice Lacking the β3 Subunit of the GABAA Receptor Have the Epilepsy Phenotype and Many of the Behavioral Characteristics of Angelman Syndrome
TLDR
The loss of the single gene, gabrb3, in these mice is sufficient to cause phenotypic traits that have marked similarities to the clinical features of AS, indicating that impaired expression of the GABRB3 gene in humans probably contributes to the overall phenotype of Angelman syndrome. Expand
...
1
2
3
4
5
...